Jacqueline Sennott
Cardiovascular Disease · Pawleys Island, SCNPI 1629411707
Payments from drug & device makers
Across 219 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$981
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$915
- Pfizer$578
- Boston Scientific$469
- E.r. Squibb & Sons, L.L.C.$395
- Boehringer Ingelheim$254
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 16 | $981 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 32 | $915 |
| Pfizer | 30 | $578 |
| Boston Scientific | 10 | $469 |
| E.r. Squibb & Sons, L.L.C. | 21 | $395 |
| Boehringer Ingelheim | 13 | $254 |
| Sanofi-aventis U.S. LLC | 2 | $210 |
| AstraZeneca | 10 | $148 |
| Johnson & Johnson | 10 | $137 |
| Novartis | 9 | $137 |
| Amgen | 8 | $134 |
| Novo Nordisk | 5 | $133 |
| Bridgebio Pharma, Inc. | 4 | $108 |
| Scpharmaceuticals Inc. | 5 | $101 |
| Merck | 6 | $100 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $84 |
| Cvrx, Inc. | 4 | $75 |
| Medtronic | 3 | $72 |
| GSK | 4 | $70 |
| Esperion Therapeutics, Inc. | 3 | $59 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $37 |
| Radius Health, Inc. | 2 | $35 |
| Baxter Healthcare | 2 | $35 |
| QOL Medical, LLC | 2 | $32 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Bayer | 1 | $20 |
| Angiodynamics, Inc. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Bracco Diagnostics Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$269
- JOT DX$243
- PRALUENT$210
- VYNDAQEL$140
- GALLANT$136
- CAMZYOS$124
- Hi-Torque Balance guide wires$108
How this compares
$5,545 in reported general payments places this provider in the 55th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 429 | $466,970 |
| EntrestoSacubitril/Valsartan | 185 | $201,174 |
| JardianceEmpagliflozin | 86 | $103,771 |
| CamzyosMavacamten | 11 | $88,452 |
| FarxigaDapagliflozin Propanediol | 83 | $77,478 |
| XareltoRivaroxaban | 35 | $49,128 |
| Repatha SureclickEvolocumab | 49 | $37,205 |
| Metoprolol Succinate | 548 | $5,555 |
| Valsartan | 103 | $5,317 |
| Ranolazine ErRanolazine | 37 | $4,936 |
| Bumetanide | 100 | $4,386 |
| Losartan Potassium | 282 | $4,129 |
| Rosuvastatin Calcium | 272 | $3,601 |
| Atorvastatin Calcium | 343 | $3,160 |
| Flecainide Acetate | 40 | $3,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $578 | $466,970429 claims |
| NovartisEntresto | $137 | $201,174185 claims |
| Boehringer IngelheimJardiance | $254 | $103,77186 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $395 | $88,45211 claims |
| AstraZenecaFarxiga | $148 | $77,47883 claims |
| Johnson & JohnsonXarelto | $137 | $49,12835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Pawleys Island
- Brent McLaurinAnderson$1.1M
- Robert BiedermanCharleston$801K
- James MerriamGreenville$728K
- Vipul ShahLancaster$488K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
- Naresh MoriRock Hill$408K
- Priya KumarGreenwood$351K
- Dev VazGreenville$257K
- William YarbroughCharleston$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.